Zotiraciclib is an investigational oral kinase inhibitor belonging to the cyclin-dependent kinase (CDK) inhibitor class, primarily under development for the treatment of aggressive cancers such as gliomas… Read more
Zotiraciclib is an investigational oral kinase inhibitor belonging to the cyclin-dependent kinase (CDK) inhibitor class, primarily under development for the treatment of aggressive cancers such as gliomas and various brain tumors. Accurate analytical characterization of this compound requires high-quality materials to ensure regulatory compliance and therapeutic safety. This collection features Zotiraciclib reference standards, along with related impurities and stable isotope-labelled compounds, essential for rigorous impurity profiling and method validation. Laboratories utilize these high-purity materials to develop robust analytical methods, conduct stability testing, and support quality control protocols during the drug development lifecycle. By incorporating these precision reference materials, researchers can reliably quantify active pharmaceutical ingredients, monitor degradation products, and track metabolic pathways with high sensitivity and accuracy throughout the investigative process.